TrialThe Lancet. Oncology2019

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

Vicky Makker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.